文献速递肝病

肝静脉压力梯度可预测MASLD患者肝功能失代偿及肝相关死亡风险

Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
PubMed 文献 · J Hepatol · 2024-05-31

这项欧洲多中心研究纳入340例基线接受HVPG测量的MASLD相关代偿期进展性慢性肝病患者,61.5%存在临床显著门脉高压(CSPH)。中位随访41.5个月,CSPH与肝失代偿风险升高(SHR 5.13)及肝相关死亡风险升高相关,HVPG每升高1 mmHg独立增加失代偿(校正SHR 1.12)和肝相关死亡(校正SHR 1.20)风险;无CSPH者短期失代偿风险极低、肝相关死亡罕见。

要点

  • MASLD-cACLD患者中61.5%存在CSPH(HVPG≥10 mmHg)。
  • CSPH者2年、5年累积失代偿发生率分别为10.0%、30.7%,无CSPH者为2.4%、9.4%。
  • HVPG每升高1 mmHg,失代偿校正SHR 1.12、肝相关死亡校正SHR 1.20(均p<0.001)。

核心结论

  • HVPG测量在MASLD-cACLD中具有高度预后价值。
  • 无CSPH的MASLD-cACLD患者短期失代偿风险极低且肝相关死亡罕见,而CSPH的存在大幅增加两者风险。

研究设计与样本

  • 欧洲多中心研究,纳入340例基线接受HVPG测量的MASLD相关代偿期进展性慢性肝病(MASLD-cACLD)患者。
  • 主要终点为肝失代偿(静脉曲张出血/腹水/肝性脑病)和肝相关死亡。

主要发现

  • 340例患者中男性56.2%,中位年龄62(55-68)岁,中位MELD 8(7-9),糖尿病占71.2%。
  • CSPH(HVPG≥10 mmHg)见于209例(61.5%)。
  • 中位随访41.5(27.5-65.8)个月,65例发生肝失代偿;CSPH者2年累积发生率10.0%、5年30.7%,无CSPH者2年2.4%、5年9.4%。
  • 无CSPH者未发生静脉曲张出血;CSPH与失代偿风险升高相关(SHR 5.13,p<0.001),HVPG每升高1 mmHg校正SHR 1.12(p<0.001)。
  • 37例发生肝相关死亡;CSPH者2年累积发生率3.3%、5年21.4%,无CSPH者5年0.8%;HVPG每升高1 mmHg与肝相关死亡风险升高独立相关(校正SHR 1.20,p<0.001)。

关键数值与推荐

  • CSPH定义为HVPG≥10 mmHg。
  • CSPH与肝失代偿风险升高相关(SHR 5.13,p<0.001)。
  • HVPG每升高1 mmHg,失代偿风险校正SHR 1.12(p<0.001),肝相关死亡风险校正SHR 1.20(p<0.001)。

临床怎么用

  • HVPG测量可为MASLD-cACLD的个体化风险分层提供重要预后信息,并可能有助于促进MASLD新型有前景治疗的研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of advanced chronic liver disease (ACLD). Portal hypertension drives hepatic decompensation and is best diagnosed by hepatic venous pressure gradient (HVPG) measurement. Here, we investigate the prognostic value of HVPG in MASLD-related compensated ACLD (MASLD-cACLD). METHODS: This European multicentre study included patients with MASLD-cACLD characterised by HVPG at baseline. Hepatic decompensation (variceal bleeding/ascites/hepatic encephalopathy) and liver-related mortality were considered the primary events of interest. RESULTS: A total of 340 patients with MASLD-cACLD (56.2% male; median age 62 [55-68] years, median MELD 8 [7-9], 71.2% with diabetes) were included. Clinically significant portal hypertension (CSPH: i.e., HVPG ≥10 mmHg) was found in 209 patients (61.5%). During a median follow-up of 41.5 (27.5-65.8) months, 65 patients developed hepatic decompensation with a cumulative incidence of 10.0% after 2 years (2Y) and 30.7% after 5 years (5Y) in those with MASLD-cACLD with CSPH, compared to 2.4% after 2Y and 9.4% after 5Y in patients without CSPH. Variceal bleeding did not occur without CSPH. CSPH (subdistribution hazard ratio [SHR] 5.13; p <0.001) was associated with an increased decompensation risk and a higher HVPG remained an independent risk factor in the multivariable model (adjusted SHR per mmHg: 1.12, p <0.001). Liver-related mortality occurred in 37 patients at a cumulative incidence of 3.3% after 2Y and 21.4% after 5Y in CSPH. Without CSPH, the incidence after 5Y was 0.8%. Accordingly, a higher HVPG was also independently associated with a higher risk of liver-related death (adjusted SHR per mmHg: 1.20, p <0.001). CONCLUSION: HVPG measurement is of high prognostic value in MASLD-cACLD. In patients with MASLD-cACLD without CSPH, the short-term risk of decompensation is very low and liver-related mortality is rare, while the presence of CSPH substantially increases the risk of both. IMPACT AND IMPLICATIONS: While the incidence of compensated advanced chronic liver disease (cACLD) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide, insights into the impact of clinically significant portal hypertension (CSPH) on the risk of liver-related events in MASLD-cACLD remain limited. Based on the findings of this European multicentre study including 340 MASLD-cACLD patients, we could show that increasing HVPG values and the presence of CSPH in particular were associated with a significantly higher risk of first hepatic decompensation and liver-related mortality. In contrast, the short-term incidence of decompensation in patients with MASLD-cACLD without CSPH was low and the risk of liver-mortality remained negligible. Thus, HVPG measurements can provide important prognostic information for individualised risk stratification in MASLD-cACLD and may help facilitate the study of novel and promising treatment possibilities for MASLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Paternostro R, Kwanten WJ, Hofer BS, et al. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD. J Hepatol. 2024. PMID: 38823501. doi:10.1016/j.jhep.2024.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。